20/20 BioLabs Partners With ROKIT To Add AI-Driven Kidney Disease Risk And Biomarker Insights To Longevity Platform

20/20 BioLabs, Inc. has partnered with ROKIT Healthcare Inc. to integrate ROKIT's chronic kidney disease prediction algorithm into its Longevity Platform, enhancing its biomarker-based disease-risk assessment tools. As part of the agreement, ROKIT will reimburse 20/20 for one-third of agreed sales and marketing expenses and may receive exclusive rights to commercialize the platform in Korea and other East Asian markets. This collaboration aims to improve patient responses to regenerative therapies by tracking inflammatory biomarkers.